Access to chloroquine in patients with rheumatic and musculoskeletal diseases attending rheumatology outpatient clinics during the COVID-19 pandemic.
S Afr Med J
; 111(8): 720-723, 2021 Jun 08.
Article
in English
| MEDLINE | ID: covidwho-1355170
ABSTRACT
Herbal medicines made from the bark of the Cinchona tree, and later quinine, have been widely used for centuries to treat medical conditions such as tropical malaria. More recently, chloroquine (CQ) and its synthetic derivatives have been used as antimalarials and to treat systemic lupus erythematosus, rheumatoid arthritis, and in the past 14 months or so, COVID-19 pneumonia. Anecdotal evidence and the erratic covering through social media of its potential efficacy in the treatment of COVID-19 pneumonia have resulted in the widespread off-label use of CQ in South Africa and worldwide. This study aimed to show that access to CQ as a chronic medication for rheumatic and musculoskeletal diseases was limited during the COVID-19 pandemic, and that this resulted in an increased incidence of flares in these patients, affecting their morbidity and potentially leading to mortality.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Rheumatology
/
Chloroquine
Type of study:
Observational study
Topics:
Traditional medicine
Limits:
Humans
Language:
English
Journal:
S Afr Med J
Year:
2021
Document Type:
Article
Affiliation country:
SAMJ.2021.v111i8.15795
Similar
MEDLINE
...
LILACS
LIS